Incyte (MEX:INCY) EBIT: MXN32,614 Mil (TTM As of Mar. 2026)


MEX:INCY Incyte Corp MEX:INCY
82 GF Score
Price MXN1,676.03
GF Value MXN1,535.76
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Incyte EBIT?

Incyte MEX:INCY 82 EBIT is MXN32,614 Mil as of Mar. 2026. GuruFocus rates MEX:INCY with a GF Score™ of 82/100 and a GF Value™ of MXN1,535.76 (Fairly Valued). The stock has 3 warning signs investors should review.

Incyte's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN6,206 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN32,614 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Incyte's annualized ROC % for the quarter that ended in Mar. 2026 was 39.66%. Incyte's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 183.06%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Incyte's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.50%.


Incyte  (MEX:INCY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Incyte's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=23382.856 * ( 1 - 11.72% )/( (53057.216 + 51033.065)/ 2 )
=20642.3852768/52045.1405
=39.66 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=125283.175 - 9048.783 - ( 64471.281 - max(0, 27281.696 - 90458.872+64471.281))
=53057.216

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=132344.023 - 9277.337 - ( 72416.168 - max(0, 26862.394 - 98896.015+72416.168))
=51033.065

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Incyte's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=24825.184/( ( (13655.613 + max(-1110.213, 0)) + (13467.506 + max(-201.931, 0)) )/ 2 )
=24825.184/( ( 13655.613 + 13467.506 )/ 2 )
=24825.184/13561.5595
=183.06 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(18445.165 + 1819.656 + 5722.77) - (9048.783 + 0 + 18049.021)
=-1110.213

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(18961.366 + 2085.013 + 5433.468) - (9277.337 + 0 + 17404.441)
=-201.931

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Incyte's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=32614.454/310679.971
=10.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incyte EBIT Related Terms


Incyte EBIT Historical Data

* Premium members only.

The historical data trend for Incyte's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte EBIT Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11,741.23 10,367.62 14,203.47 6,651.09 30,013.32

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,804.61 10,518.10 8,858.41 7,031.64 6,206.30

MEX:INCY vs MRNA, ROIV, INSM: EBIT Comparison

For the Biotechnology subindustry, Incyte's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Incyte's EV-to-EBIT falls into.


MEX:INCY
82GF Score
Incyte Corp MEX:INCY
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN32,614 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN32,614 Mil mean?
Incyte (MEX:INCY) has a EBIT of MXN32,614 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Incyte.
Is Incyte's EBIT too high?
Incyte's current EBIT is MXN32,614 Mil. Overall, Incyte has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Incyte's EBIT compare to MRNA and ROIV?
Incyte's EBIT of MXN32,614 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Incyte. Incyte's current EBIT is MXN32,614 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Fairly Valued. The stock's GF Value™ is MXN1,535.76, compared to a current price of MXN1,676.03 — trading 9.1% above its estimated fair value. The current EBIT is MXN32,614 Mil. Incyte's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Incyte (MEX:INCY), the current EBIT is MXN32,614 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN1,676.03 is trading 9.1% above its estimated GF Value™ of MXN1,535.76. GuruFocus considers Incyte to be Fairly Valued.

Key valuation signals for MEX:INCY:

  • EBIT: MXN32,614 Mil
  • GF Value™: MXN1,535.76 vs. price of MXN1,676.03 (9.1% above fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
82GF Score

Get the complete analysis for MEX:INCY

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,676.03
Price
MXN1,535.76
GF Value